Intervals Lengthened, Costs Lowered By HPV DNA Primary Screening – ACS
This article was originally published in The Gray Sheet
Executive Summary
Cervical cancer screening with human papillomavirus DNA tests in conjunction with cytology is sufficiently sensitive to permit widened screening intervals, the American Cancer Society finds Nov. 15
You may also be interested in...
HPV DNA Pap Test Approved As Primary Screen; New Guidelines Expected
Digene is evaluating various methods of marketing its human papillomavirus (HPV) test to ob/gyn physicians following expanded approval for primary cervical cancer screening March 31
HPV DNA Pap Test Approved As Primary Screen; New Guidelines Expected
Digene is evaluating various methods of marketing its human papillomavirus (HPV) test to ob/gyn physicians following expanded approval for primary cervical cancer screening March 31
Cytyc Prepares To Launch ThinPrep Imager; Women’s Health Recap For 2002
Cytyc's ThinPrep and TriPath's SurePath liquid-based cytology Pap tests could receive a boost in 2003 from a positive NICE technology assessment review